Additional Proxy Soliciting Materials (definitive) (defa14a)
26 Maio 2023 - 5:23PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
| | | | | | | | | | | | | | |
Filed by the Registrant ☒ | | | |
Filed by a Party other than the Registrant ☐ | | | |
Check the appropriate box: | | | |
☐ | Preliminary Proxy Statement | | | |
☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☐ | Definitive Proxy Statement | | | |
☒ | Definitive Additional Materials | | | |
☐ | Soliciting Material Pursuant to §240.14a-12 | |
| | | | | | | | | | | | | | |
GRI BIO, INC. |
(Name of Registrant as Specified in Its Charter) |
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
| | | | | | | | | | | | | | |
Payment of Filing Fee (Check the appropriate box): |
☒ | No fee required |
☐ | Fee paid previously with preliminary materials |
☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
Vallon Pharmaceuticals (NASDAQ:VLON)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Vallon Pharmaceuticals (NASDAQ:VLON)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024